Private Medicare plans must cover Biogen's ALS drug, US agency says
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...
Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...
North Texas runner with ALS aims for 100 marathons with support from family & friends
It's a gray morning at Grapevine Lake, but people are showing up to run laps around the marina. That includes Troy Pruett.
How ALS hasn’t stopped a Dallas Marathon competitor from reaching meteoric running heights
Troy Pruett, a Grapevine resident, will be competing in his 96th marathon this weekend and getting one step closer to the ...
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...
Biogen ALS drug needs to be covered by MA plans, CMS says
CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...
FierceBiotech2d
Corcept's cortisol modulator fails to slow ALS decline, linked to 'gastrointestinal upset' at onset
Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...
Seacoast fire departments eye new paramedic service after Exeter Hospital ends ALS
Exeter Hospital announced in the fall that it plans to terminate its ALS service. Here's how Seacoast fire departments are ...
TMCnet4d
New ALS Association-Led Research Finds Specialists Diagnose ALS Twice as Fast as General Neurologists
The research, led by the ALS Association in collaboration with several leading ALS clinicians, examined Medicare claims made from 2011 to 2021 and found that the average time for ...
ALS News Today10d
Utreloxastat fails to slow ALS disease progression in Phase 2 trial
The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...